AMD, IBM, CIT, SGP, KR, MRK With Highest Daily Short Volume On NYSE Friday

  amd-ibm-cit-sgp-kr-mrk-with-highest-daily-short-volume-on-nyse-friday.html
  Stocks and Investing on Sat, Oct 10th, 2009 by WOPRAI

October 12, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NYSE Daily Short Volume Report for Friday, October 9th, 2009 and come to the following statistical conclusions. There were 6,415 stocks with daily short volume reported and total NYSE trading volume of 838,108,384 shares. Total Daily Short Volume was 397,444,534 shares. 47.42% of all trading on the NYSE Friday was short selling. The chart below highlights 6 stocks that had the highest daily short volume on Friday. Advanced Micro Devices (NYSE: AMD), International Business Machines (NYSE: IBM), CIT Group (NYSE: CIT), Schering Plough (NYSE: SGP), Kroger (NYSE: KR) and Merck (NYSE: MRK). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Date Symbol Short Volume Total Volume Market Percent

20091009 AMD 1,427,824 2,580,548 P 55.33%

20091009 IBM 1,284,647 1,957,920 P 65.61%

20091009 CIT 1,109,503 2,754,076 P 40.29%

20091009 SGP 914,149 1,653,729 P 55.28%

20091009 KR 839,688 1,426,595 P 58.86%

20091009 MRK 817,169 1,269,854 P 64.35%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Advanced Micro Devices, Inc. (NYSE: AMD), a semiconductor company, provides processing solutions for the computing, graphics, and consumer electronics markets in the United States, Canada, Europe, and Asia. It offers microprocessor products, including servers and workstation microprocessors, notebook microprocessors, and desktop microprocessors; embedded processor products; chipset products, including IGP and discrete chipsets; and graphics products, such as 3D graphics, and video and multimedia products for use in desktop and notebook personal computers (PCs), including home media PCs, professional workstations, and servers, as well as technology for game consoles. The company serves original equipment manufacturers, original design manufacturers, and third-party distributors through direct sales force and independent sales representatives. It has a strategic relationship with StudioGPU. The company was founded in 1969 and is headquartered in Sunnyvale, California.

International Business Machines Corporation (NYSE: IBM) develops and manufactures information technology products and services worldwide. Its Global Technology Services segment offers IT infrastructure and business process services, such as strategic outsourcing, integrated technology, business transformation outsourcing, and maintenance. The companya�s Global Business Services segment provides professional services and application outsourcing services, including consulting and systems integration, and application management. Its Systems and Technology segment offers computing and storage solutions, including servers, disk and tape storage systems and software, semiconductor technology and products, packaging solutions, engineering and technology services, and retail store solutions. IBMa�s Software segment primarily offers middleware and operating systems software comprising WebSphere software for Web-enabled applications; information management software for database, content management, information integration and business intelligence; Tivoli software for infrastructure management, including security and storage management; Lotus software for collaboration, messaging, and social networking; and rational software, a process automation tool. The companya�s Global Financing segment provides commercial financing to dealers and remarketers of IT products; lease and loan financing to external and internal clients; and sale and lease of used equipment. IBM serves banking, insurance, education, government, healthcare, life sciences, aerospace and defense, automotive, chemical and petroleum, electronics, distribution, telecommunications, media and entertainment, and energy and utilities, as well as small and medium sized business. The company was formerly known as Computing-Tabulating-Recording Co. and changed its name to International Business Machines Corporation in 1924. IBM was founded in 1910 and is based in Armonk, New York.

CIT Group Inc. (NYSE: CIT) operates as the holding company for CIT bank that provides commercial financing and leasing products, and management advisory services to the small and middle market companies worldwide. Its products principally include asset based loans; secured lines of credit; operating, capital, and leveraged leases; vendor finance programs; import and export financing; debtor-in-possession/turnaround financing; acquisition and expansion financing; letters of credit/trade acceptances structuring; and small business loans. The companya�s services primarily comprise financial risk management; asset management and servicing; merger and acquisition advisory services; debt restructuring; credit protection; accounts receivable collection; debt underwriting and syndication; capital markets; and insurance services for small businesses and middle market customers. It serves clients in various industries, including transportation, particularly aerospace and rail, manufacturing, wholesaling, retailing, healthcare, communications, media and entertainment, and various service-related industries. The company was founded in 1908 and is headquartered in New York, New York.

Schering-Plough Corporation (NYSE: SGP) discovers, develops, manufactures, and sells pharmaceuticals worldwide. It operates in three segments: Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. The Prescription Pharmaceuticals segment offers human pharmaceutical products in six therapeutic areas, including cardiovascular, central nervous system, immunology and infectious disease, oncology, respiratory, and womena�s health. This segment sells its products through wholesale and specialty distributors, hospitals, managed care organizations, retail and specialty pharmacists, and government agencies. The Animal Health segment discovers, develops, manufactures, and markets animal health products, including vaccines. Its products include livestock products, poultry products, companion animal products, and aquaculture products. This segment offers its products to veterinarians, distributors, and animal producers. The Consumer Health Care segment manufactures and sells over-the-counter, foot care, and sun care products. This segment sells its products through wholesale and retail drug, food chain, and mass merchandiser outlets. The company has a collaboration agreement with Alder Biopharmaceuticals Inc. to identify therapeutic monoclonal antibody lead candidates for central nervous system disorders. Schering-Plough Corporation was founded in 1928 and is headquartered in Kenilworth, New Jersey.

The Kroger Co. (NYSE: KR), together with its subsidiaries, operates as a food retailer in the United States. The company operates supermarkets under four formats: combination food and drug stores (combo stores), multi-department stores, marketplace stores, or price impact warehouses. The combo stores operate as food stores that offer specialty departments, including natural food and organic sections, pharmacies, general merchandise, and pet centers, as well as perishables, such as fresh seafood and organic produce. The multi-department stores sell a selection of general merchandise items, which include apparel, home fashion and furnishings, electronics, automotive products, toys, and fine jewelry. The marketplace stores offer full-service grocery and pharmacy departments, as well as a general merchandise area that includes outdoor living products, electronics, home goods, and toys. The combo, multi department, and marketplace stores also have fuel centers. The price impact warehouse stores offer grocery, health, and beauty care items, such as meat, dairy, baked goods, and fresh produce items. The Kroger Co. also manufactures and processes food for sale in its supermarkets. In addition, the company operates fine jewelry stores; and convenience stores, which offer an assortment of staple food items and general merchandise, as well as gasoline. As of January 31, 2009, the company operated approximately 2,481 supermarkets and multi-department stores under two dozen banners, including Kroger, Ralphs, Fred Meyer, Food 4 Less, King Soopers, Smitha�s, Frya�s, Frya�s Marketplace, Dillons, QFC, and City Market, of which 781 stores had fuel centers, as well as operated approximately 771 convenience stores and 385 fine jewelry stores. The Kroger Co. was founded in 1883 and is based in Cincinnati, Ohio.

Merck & Co., Inc. (NYSE: MRK) provides products for human and animal health in the United States and internationally. The companya�s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.a�s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net